AEON Biopharma, Inc. (AEON)

AEON Biopharma Statistics

Total Valuation

AEON Biopharma has a market cap or net worth of $23.03 million. The enterprise value is $56.27 million.

Market Cap	23.03M
Enterprise Value	56.27M

Important Dates

The next estimated earnings date is Thursday, May 14, 2026, after market close.

Earnings Date	May 14, 2026
Ex-Dividend Date	n/a

Share Statistics

AEON Biopharma has 25.30 million shares outstanding. The number of shares has increased by 1,622.66% in one year.

Current Share Class	25.30M
Shares Outstanding	25.30M
Shares Change (YoY)	+1,622.66%
Shares Change (QoQ)	+10.80%
Owned by Insiders (%)	13.54%
Owned by Institutions (%)	10.58%
Float	9.87M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.49

Current Ratio	0.49
Quick Ratio	0.44
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-234.17%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	1,219.30%
Weighted Average Cost of Capital (WACC)	3.14%
Revenue Per Employee	n/a
Profits Per Employee	-$4.90M
Employee Count	8
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +84.21% in the last 52 weeks. The beta is 0.66, so AEON Biopharma's price volatility has been lower than the market average.

Beta (5Y)	0.66
52-Week Price Change	+84.21%
50-Day Moving Average	1.02
200-Day Moving Average	0.95
Relative Strength Index (RSI)	42.47
Average Volume (20 Days)	130,866

Short Selling Information

The latest short interest is 103,230, so 0.41% of the outstanding shares have been sold short.

Short Interest	103,230
Short Previous Month	278,199
Short % of Shares Out	0.41%
Short % of Float	1.05%
Short Ratio (days to cover)	0.80

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-16.30M
Pretax Income	-39.22M
Net Income	-39.22M
EBITDA	-16.22M
EBIT	-16.30M
Earnings Per Share (EPS)	-$3.95

Balance Sheet

The company has $3.01 million in cash and $35.75 million in debt, with a net cash position of -$32.74 million or -$1.29 per share.

Cash & Cash Equivalents	3.01M
Total Debt	35.75M
Net Cash	-32.74M
Net Cash Per Share	-$1.29
Equity (Book Value)	-55.03M
Book Value Per Share	-4.55
Working Capital	-3.50M

Cash Flow

In the last 12 months, operating cash flow was -$17.31 million and capital expenditures -$4,000, giving a free cash flow of -$17.31 million.

Operating Cash Flow	-17.31M
Capital Expenditures	-4,000
Depreciation & Amortization	78,000
Net Borrowing	n/a
Free Cash Flow	-17.31M
FCF Per Share	-$0.68

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

AEON Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1,622.66%
Shareholder Yield	-1,622.66%
Earnings Yield	-166.69%
FCF Yield	-73.58%

Analyst Forecast

The average price target for AEON Biopharma is $7.20, which is 691.21% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$7.20
Price Target Difference	691.21%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on February 26, 2025. It was a reverse split with a ratio of 1:72.

Last Split Date	Feb 26, 2025
Split Type	Reverse
Split Ratio	1:72

Scores

Altman Z-Score	n/a
Piotroski F-Score	2